Adult w/ normal renal functionAcute bacterial sinusitis 500 mg once daily for 10-14 days. Acute bacterial exacerbations of chronic bronchitis 500 mg once daily for 7- 10 days. Community-acquired pneumonia 500 mg once daily or bd for 7-14 days. Pyelonephritis 500 mg once daily for 7-10 days. Complicated UTI 500 mg once daily for 7-14 days. Uncomplicated cystitis 250 mg once daily for 3 days. Chronic bacterial prostatitis 500 mg once daily for 28 days. Complicated skin & soft tissue infections 500 mg once daily or bd for 7-14 days. Inhalation anthrax 500 mg once daily for 8 wk.
May be taken with or without food: Take at least 2 hr before or after Fe salts, antacids & sucralfate. Ensure adequate fluid intake. May be divided along the score line. Swallow whole, do not crush.
Contraindications
Hypersensitivity to levofloxacin or other quinolones. Epilepsy, history of tendon disorders related to fluoroquinolone administration. Childn or growing adolescents. Pregnancy & lactation.
Hypersensitivity reactions. Not recommended for treatment of known or suspected MRSA infections unless susceptibility to levofloxacin is confirmed. Reserve levofloxacin for use in patients who have no alternative treatment options for the following indications: Uncomplicated UTI, acute bacterial exacerbation of chronic bronchitis, acute bacterial sinusitis. Risk of tendinitis & tendon rupture especially in patients >60 yr, in patients receiving daily dose of 1,000 mg & patients using corticosteroids. Clostridium difficile-associated disease (CDAD). May lower seizure threshold & may trigger seizures. Discontinue if convulsive seizure occurs. Increased risk for haemolytic reaction in patients w/ G6PD deficiency. Severe bullous skin reactions eg, Stevens-Johnson syndrome or toxic epidermal necrolysis. Dysglycaemia usually in diabetic patients receiving concomitant oral hypoglycaemic agent or insulin. Photosensitisation. Psychotic reactions. Patients w/ known risk factors for prolongation of the QT interval. Exacerbation of myasthenia gravis. Hepatobiliary disorders. Peripheral neuropathy. Vision disorders. Prolonged use may result in overgrowth of non-susceptible organisms. Increased risk of aortic aneurysm & dissection particularly in the older population. False positive results in the determination of opiates in urine. False negative results in bacteriological diagnosis of TB. Concomitant use w/ vit K antagonist (eg, warfarin). May impair ability to drive or operate machinery. Patients w/ renal impairment.
Reduced absorption w/ Fe salts, Mg- or Al-containing antacids, didanosine, multivit containing Zn. Reduced bioavailability w/ sucralfate. Pronounced lowering of the cerebral seizure threshold w/ theophylline, NSAIDs or other agents which lower seizure threshold. Increased conc w/ fenbufen. Reduced renal clearance w/ cimetidine & probenecid. Increased t½ of ciclosporin. Increased coagulation tests (PT/INR) &/or bleeding w/ vit K antagonist eg, warfarin. Caution when co-administered w/ drugs known to prolong QT interval (eg, class IA & III antiarrhythmics, TCAs, macrolides, antipsychotics).
Sign Out
